Genocea Biosciences, a privately-held vaccine developer in Cambridge, MA, said it has added Staph Bakali to its board as executive director. Bakali was formerly the chief operating officer of ID Biomedical, a Vancouver, BC-based vaccine developer that was acquired by drug giant GlaxoSmithKline in 2005 for $1.4 billion. Genocea is working on a variety of vaccine projects, including one we wrote about in collaboration with Seattle-based PATH to prevent pneumococcal infections.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
